Product Images Finasteride

The text appears to be a section of a chart or graph displaying the Mean Change from Baseline + 1 SE in Symptom Score in 2 Long Term Efficacy and Safety Study with Placebo and Finasteride over the course of Baseline, Year 1, Year 2, Year 3, and Year 4. Therefore, it is not a useful description, but rather information extracted from a larger document.*

The text describes a graph (Figure 3) showing the percentage of patients who developed Acute Urinary Retention over a period of time in two groups: those taking Finasteride and those taking a Placebo. The graph shows more patients in the Finasteride group experienced Acute Urinary Retention compared to Placebo. The text also includes data on the number of events and risk per year for each group.*

This is a graph showing the mean percent change from the baseline in prostate volume over four years in a long-term study evaluating the efficacy and safety of finasteride compared to a placebo. The study included 155 participants in the placebo group and 157 participants in the finasteride group. The graph shows that the finasteride group had a decrease in prostate volume compared to the placebo group over the four-year study period.*

The text describes a graph or figure showing the percentage of individuals experiencing a 4-point increase in AUA Symptom Score over time for different treatment groups. The x-axis indicates the years from randomized treatment while the y-axis shows the percentage with an event (4-point rise in score).*

This is a description of a medication called Finasteride 5mg. The medicine is packaged by a company called Bryant Ranch Prepack Burkbank, located in California. The tablet has a blue round shape and should be stored at room temperature, which is between 20°C-25°C (68°F-77°F). This medication is a generic version of Proscar 5mg Tablet, produced by Rising Health LLC. The National Drug Code assigned to this medication is 7133515301 015851001523487.*